The relative risks of a low-nitrosamine smokeless tobacco product compared with smoking cigarettes: estimates of a panel of experts.

@article{Levy2004TheRR,
  title={The relative risks of a low-nitrosamine smokeless tobacco product compared with smoking cigarettes: estimates of a panel of experts.},
  author={David T Levy and Elizabeth A. Mumford and Kenneth Michael Cummings and Elizabeth A. Gilpin and Gary A. Giovino and Andrew Hyland and David T Sweanor and Kenneth E. Warner},
  journal={Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology},
  year={2004},
  volume={13 12},
  pages={2035-42}
}
A nine-membered panel of experts was asked to determine expert opinions of mortality risks associated with use of low-nitrosamine smokeless tobacco (LN-SLT) marketed for oral use. A modified Delphi approach was employed. For total mortality, the estimated median relative risks for individual users of LN-SLT were 9% and 5% of the risk associated with smoking for those ages 35 to 49 and > or =50 years, respectively. Median mortality risks relative to smoking were estimated to be 2% to 3% for lung… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 4 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 104 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 46 references

Similar Papers

Loading similar papers…